Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance
Clinical Pharmacology & Therapeutics · 13.08.2026
DOI: 10.1002/cpt.70400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 13.08.2026. Verfasst von Luis C Pinheiro und 9 weiteren Autor:innen. Beteiligte Einrichtung: European Medicines Agency, Amsterdam, The Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Regulatory bodies play a central role in providing guidance that enables safe and effective use of artificial intelligence tools in medicine development and evaluation. Regulators can also act as catalysts for regulatory science research. To inform these efforts, a European‐wide survey was conducted to solicit stakeholder perspectives on the priority areas for regulatory science research related to the use of artificial intelligence in the medicine lifecycle. Twenty‐eight regulatory science research questions were developed covering seven thematic domains: (1) research integrity and intellectual property; (2) accuracy and reliability of AI tools; (3) data governance, confidentiality, and consent; (4) regulation and oversight; (5) ethics, fairness, and bias prevention; (6) resources and support for AI use; and (7) impact on jobs and skills. Within each domain, stakeholders ranked four research challenges. A total of 273 responses were collected from regulators, pharmaceutical industry professionals, patients and consumers, academics, and healthcare professionals. Rankings of research challenges frequently converged across stakeholder groups and levels of AI experience. The top‐ranked research questions within each domain were weighted according to the overall importance ranking of each domain to identify a list of 10 priority areas of research. The majority of the 10 priority areas fell within the domains of “Accuracy and reliability of AI tools,” “Data governance, confidentiality, and consent,” and “Ethics, fairness, and bias prevention.” This list aims to support researchers and research funding bodies in addressing knowledge gaps on artificial intelligence in the medicines lifecycle.
Autor:innen und Institutionen
- European Medicines Agency, Amsterdam, The Netherlands.
- The Dental and Pharmaceutical Benefits Agency, Stockholm, Sweden.
- Federal Institute for Drugs and Medical Devices, Bonn, Germany.
- European Patients' Forum, Brussels, Belgium.
- Medicines Evaluation Board, Utrecht, The Netherlands.
- Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands.
ORCID-Profile: Luis C Pinheiro, Amanda C Langston, Gabriel Westman
Zitieren
APA
Pinheiro, L. C., Langston, A. C., Orre, M., Zinserling, J., Boumaki, K., Hornung, B. V. H., O'Sullivan, S., Westman, G., Broich, K., & Arlett, P. (2026). Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70400
Vancouver
Pinheiro LC, Langston AC, Orre M, Zinserling J, Boumaki K, Hornung BVH, et al. Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70400
BibTeX
@article{Pinheiro2026,
author = {Pinheiro, Luis C and Langston, Amanda C and Orre, Marie and Zinserling, Joerg and Boumaki, Konstantina and Hornung, Bastian V H and O'Sullivan, Siobhan and Westman, Gabriel and Broich, Karl and Arlett, Peter},
title = {Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70400}
}
EUVIMED